Cargando…

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia

PURPOSE: The early diagnosis of sickle cell disease (SCD) patients and getting appropriate treatment are crucial for improving clinical outcomes. This study aims to assess the use of hydroxyurea among patients diagnosed with SCD and assess factors influencing the attitude toward the medication and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gohal, Gassem A, Gosadi, Ibrahim M, Cittana Iqbal, Basheer Ahmed, Ghazwani, Yahya H, Daghriri, Amal M, Shugairi, Ahmad A, Daghriri, Khaled A, Zurayyir, Atyaf J, Nemri, Abdulrhman A, Abdulhaq, Monera A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653045/
https://www.ncbi.nlm.nih.gov/pubmed/36387052
http://dx.doi.org/10.2147/PPA.S390568
_version_ 1784828603452620800
author Gohal, Gassem A
Gosadi, Ibrahim M
Cittana Iqbal, Basheer Ahmed
Ghazwani, Yahya H
Daghriri, Amal M
Shugairi, Ahmad A
Daghriri, Khaled A
Zurayyir, Atyaf J
Nemri, Abdulrhman A
Abdulhaq, Monera A
author_facet Gohal, Gassem A
Gosadi, Ibrahim M
Cittana Iqbal, Basheer Ahmed
Ghazwani, Yahya H
Daghriri, Amal M
Shugairi, Ahmad A
Daghriri, Khaled A
Zurayyir, Atyaf J
Nemri, Abdulrhman A
Abdulhaq, Monera A
author_sort Gohal, Gassem A
collection PubMed
description PURPOSE: The early diagnosis of sickle cell disease (SCD) patients and getting appropriate treatment are crucial for improving clinical outcomes. This study aims to assess the use of hydroxyurea among patients diagnosed with SCD and assess factors influencing the attitude toward the medication and the reasons for discontinuation. METHODS: This study was a cross-sectional investigation targeting parents or caregivers of children diagnosed with SCD in the Jazan region of Saudi Arabia. Data were collected from tertiary healthcare hospitals via a self-administered questionnaire. The questionnaire was composed of sections measuring the participants’ demographics, the number of children diagnosed with SCD, the use of hydroxyurea, and the parents’ beliefs about hydroxyurea. RESULTS: There were 301 parents or caregivers recruited. The majority of the recruited participants were mothers (54.5%), and nearly half of the sample were older than 35. More than 80% of the participants declare that one or more of their children are receiving hydroxyurea to manage SCD. The majority of participants declared that using hydroxyurea reduced the frequency of body pain episodes, emergency department visits, and hospital admissions. Participants’ major concern about the use of hydroxyurea was related to the fear of weakening their immunity (29.5%) and hydroxyurea’s perceived effect on fertility (16.8%). Furthermore, 52 (18%) of the participants declared that the use of hydroxyurea to manage the disease was stopped; the main reasons for stopping was their belief that hydroxyurea had side effects and its impact on weakening of their immune system. CONCLUSION: The findings indicate the importance of increasing the role of clinicians in educating patients and caregivers about the use of hydroxyurea and its benefits.
format Online
Article
Text
id pubmed-9653045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96530452022-11-15 Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia Gohal, Gassem A Gosadi, Ibrahim M Cittana Iqbal, Basheer Ahmed Ghazwani, Yahya H Daghriri, Amal M Shugairi, Ahmad A Daghriri, Khaled A Zurayyir, Atyaf J Nemri, Abdulrhman A Abdulhaq, Monera A Patient Prefer Adherence Original Research PURPOSE: The early diagnosis of sickle cell disease (SCD) patients and getting appropriate treatment are crucial for improving clinical outcomes. This study aims to assess the use of hydroxyurea among patients diagnosed with SCD and assess factors influencing the attitude toward the medication and the reasons for discontinuation. METHODS: This study was a cross-sectional investigation targeting parents or caregivers of children diagnosed with SCD in the Jazan region of Saudi Arabia. Data were collected from tertiary healthcare hospitals via a self-administered questionnaire. The questionnaire was composed of sections measuring the participants’ demographics, the number of children diagnosed with SCD, the use of hydroxyurea, and the parents’ beliefs about hydroxyurea. RESULTS: There were 301 parents or caregivers recruited. The majority of the recruited participants were mothers (54.5%), and nearly half of the sample were older than 35. More than 80% of the participants declare that one or more of their children are receiving hydroxyurea to manage SCD. The majority of participants declared that using hydroxyurea reduced the frequency of body pain episodes, emergency department visits, and hospital admissions. Participants’ major concern about the use of hydroxyurea was related to the fear of weakening their immunity (29.5%) and hydroxyurea’s perceived effect on fertility (16.8%). Furthermore, 52 (18%) of the participants declared that the use of hydroxyurea to manage the disease was stopped; the main reasons for stopping was their belief that hydroxyurea had side effects and its impact on weakening of their immune system. CONCLUSION: The findings indicate the importance of increasing the role of clinicians in educating patients and caregivers about the use of hydroxyurea and its benefits. Dove 2022-11-08 /pmc/articles/PMC9653045/ /pubmed/36387052 http://dx.doi.org/10.2147/PPA.S390568 Text en © 2022 Gohal et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gohal, Gassem A
Gosadi, Ibrahim M
Cittana Iqbal, Basheer Ahmed
Ghazwani, Yahya H
Daghriri, Amal M
Shugairi, Ahmad A
Daghriri, Khaled A
Zurayyir, Atyaf J
Nemri, Abdulrhman A
Abdulhaq, Monera A
Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
title Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
title_full Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
title_fullStr Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
title_full_unstemmed Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
title_short Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
title_sort utilization of hydroxyurea among patients diagnosed with sickle cell disease in jazan, saudi arabia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653045/
https://www.ncbi.nlm.nih.gov/pubmed/36387052
http://dx.doi.org/10.2147/PPA.S390568
work_keys_str_mv AT gohalgassema utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT gosadiibrahimm utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT cittanaiqbalbasheerahmed utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT ghazwaniyahyah utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT daghririamalm utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT shugairiahmada utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT daghririkhaleda utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT zurayyiratyafj utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT nemriabdulrhmana utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia
AT abdulhaqmoneraa utilizationofhydroxyureaamongpatientsdiagnosedwithsicklecelldiseaseinjazansaudiarabia